IN THIS ISSUE

Carol Milano
Employers believe in this hybrid approach. Is it time for medical insurers to look at it carefully?
Peer-Reviewed
Debra Wertz, PharmD
Likun Hou, MS
Andrea DeVries, PhD
The program showed significant improvements in all diabetes and hypertension-related clinical measures
Legislation & Regulation
John Carroll
The new system is supposed to have transparent pricing, but some say it is susceptible to manipulation, which was AWP’s downfall
Medication Management
Thomas Reinke
Developers make progress with genetic markers aimed at improving drug response
Tomorrow's Medicine
Thomas Morrow, MD
The FDA will make a final determination on regulations intended to permit the sale of ‘follow-on’ biologics
News & Commentary